“Sadly, people affected by this disease, which currently is one of the few cancers with little or no progress in treatments, have now been dealt a double negative of bad news, with today’s decision from NICE coming in the wake of Abraxane, in combination with gemcitabine, also being removed from the Cancer Drugs Fund list.